Cancer science
Frontline ATRA-ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG-APL2017 Trial.
Ken Takase, Tomohiko Kamimura, Takuro Kuriyama, Takahito Tokuyama, Hideho Henzan, Yoshikane Kikushige, Ilseung Choi, Yutaka Imamura, Akio Mori, Shuki Ohya, Noriaki Kawano, Koji Yonemoto, Mine Harada, Koichi Akashi, Toshihiro Miyamoto
Published: 202610.1111/cas.70328
Abstract
All-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) has become the international standard of care for newly diagnosed acute promyelocytic leukemia (APL), demonstrating superior efficacy and safety over ATRA-chemotherapy regimens. Howe…
Preview only. Read the full abstract at the source